Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Completed · Phase 1

Conditions studied: Advanced Malignancies, Solid Tumor, Hematological Malignancy

In brief

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

Key facts

Study ID

NCT05391022

Run by

Constellation Pharmaceuticals

People needed

35

Starts

2021-07-20

Expected to finish

2024-02-29

Last updated by the study team

2025-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Confirmed diagnosis of an advanced malignancy for which no effective standard treatment options are available
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

You may not qualify if…

• Chronic or active conditions and/or concomitant medication use that would prohibit treatment

Where it is running

• Gabrail Cancer Center Research — Canton, Ohio, United States
• Gettysburg Cancer Center — Gettysburg, Pennsylvania, United States
• Start Mountain Region — West Valley City, Utah, United States
• Hight Technology Hospital Medcenter — Batumi, Georgia
• K. Eristavi National Center of Experimental and Clinical Surgery — Tbilisi, Georgia
• Simon Khechinashvili University Hospital — Tbilisi, Georgia
• Barcelona HM Nou Delfos — Barcelona, Spain
• Madrid - FJD — Madrid, Spain
• START CIOCC Hospital HM Sanchinarro — Madrid, Spain
• Hospital Universitario Virgen del Rocío — Seville, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.